ACRV Acrivon Therapeutics Inc

Price (delayed)

$1.55

Market cap

$66.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2

Enterprise value

$34.5M

?
Relative Growth: Rel. Growth: 8
Relative Strength: Rel. Strength: 42
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 8

We are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our ...

Highlights
Acrivon Therapeutics's debt has decreased by 31% YoY and by 11% QoQ
The EPS has grown by 10% YoY
ACRV's quick ratio is down by 20% YoY but it is up by 17% from the previous quarter
ACRV's equity is down by 40% YoY and by 15% QoQ

Key stats

What are the main financial stats of ACRV

ACRV stock price

How has the Acrivon Therapeutics stock price performed over time
Intraday
2.65%
1 week
-4.91%
1 month
-28.57%
1 year
26.02%
YTD
-35.68%
QTD
11.51%

Financial performance

How have Acrivon Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$82.35M
Net income
-$77.27M
Gross margin
N/A
Net margin
N/A
The operating income has increased by 12% year-on-year and by 2.1% since the previous quarter
ACRV's net income is up by 8% year-on-year

Price vs fundamentals

How does ACRV's price correlate with its fundamentals

Growth

What is Acrivon Therapeutics's growth rate over time

Valuation

What is Acrivon Therapeutics stock price valuation
P/E
N/A
P/B
0.63
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 10% YoY
ACRV's equity is down by 40% YoY and by 15% QoQ
The P/B is 22% above the last 4 quarters average of 0.5

Efficiency

How efficient is Acrivon Therapeutics business performance
The ROIC has plunged by 63% YoY and by 17% from the previous quarter
Acrivon Therapeutics's return on equity has decreased by 44% YoY and by 13% QoQ
The ROA has contracted by 40% YoY and by 12% from the previous quarter

Dividends

What is ACRV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACRV.

Financial health

How did Acrivon Therapeutics financials performed over time
The total assets is down by 39% year-on-year and by 17% since the previous quarter
ACRV's total liabilities is down by 28% since the previous quarter and by 23% year-on-year
Acrivon Therapeutics's debt is 97% lower than its equity
The debt to equity has surged by 50% since the previous quarter and by 50% year-on-year
ACRV's equity is down by 40% YoY and by 15% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.